Inovio Pharmaceuticals, Inc. INO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Inovio Pharmaceuticals, Inc. (INO) is a healthcare company listed in the US with a market value of about $268M. In the twelve months to September 30, 2026 it had revenue of $298901 and net income of -$71M, a net margin of -23798.9%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -61% a year, a 5-year average ROIC of -137%.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $10M in 2014 to $65343 in 2025, a decline of about 37.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 136% over three years (dilution for shareholders). It spends 82957% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $298901 | $65343 | $217756 | $832010 | $10M | $2M | $7M | $4M | $30M | $42M | $35M |
| Net income | -$71M | -$85M | -$107M | -$135M | -$280M | -$304M | -$166M | -$119M | -$97M | -$88M | -$74M |
| Free cash flow | -$74M | -$89M | -$105M | -$125M | -$217M | -$217M | -$179M | -$99M | -$76M | -$74M | -$65M |
| EPS (diluted) | $-0.59 | $-0.45 | $-0.99 | $-1.52 | $-3.52 | $-4.36 | $-3.21 | $-3.63 | $-3.15 | $-3.27 | $-3.03 |
| Net margin | -23798.9% | -130000.0% | -49254.3% | -16239.9% | -2726.7% | -17109.9% | -2245.4% | -2902.8% | -318.1% | -208.9% | -208.5% |
| ROIC | — | -259.4% | -139.8% | -110.1% | -105.2% | -72.1% | -25.8% | -427.8% | -67.9% | -58.7% | -61.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $6.33, 343% above the current price; targets range from $5.00 to $8.00; the consensus rating is “Strong buy”; expected EPS is $-0.90 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Inovio Pharmaceuticals pay a dividend?
Not currently.
Is Inovio Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Inovio Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.